nathan chen

Serve as a key member of the executive team. Oversee and responsible for OBI portfolio clinical development strategy, planning and implementation. Supervise and direct Clinical Research Teams, including Clinical/Medical Sciences, Biostatistics, Safety & Pharmacovigilance, and Clinical Operations. Lead and work collaboratively with R&D, Regulatory and Commercial teams to ensure alignment and a seamless transition from the R&D to Commercial phases of development of OBI’s global pipeline (Immunotherapy in oncology)

* Provide consultation services on * Portfolio selection or management * Clinical development strategy & planning * Biologics or Chemical Drug, across Therapeutic Area * Biopharmaceuticals or Devices Development * Asset evaluation, development plan & risk management, commercialization risk assessment * Enhanced Clinical Trial Design (ECTD) & Enhanced Quantitative Drug Development (EQDD) * Trial design and implementation planning for all phases * Medical monitoring & Pharmacovigilance planning and management

Serves as the key interface on Development Assets for Asia and provides coordination (“One Pfizer”) between EMBU, PCBU, SCBU, OBU Global Teams, WRD, China PCO Medical & Regulatory, China DevOps, RMM’s, Asia China R&D Center and various Platform Functions and the country/regional organizations in Asia, with a primary focus on China. Manages and coaches a Group of Clinical Scientists working as the primary study clinicians of clinical trials for China/Asia registration in support of Emerging Market Business Unit objectives in China/Asia across Disease Areas.